Does treatment with the GLP-1 receptor agonist semaglutide reduce alcohol intake in patients with alcohol use disorder and comorbid obesity?
Funder: Novo Nordisk Fonden
Amount: DKK 5,466,000
Funding type: research
Start date: 2022-01-01
Investigator: Anders Fink-Jensen (lead)
Institution: Psykiatrisk Center København
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 0
Funder award ID: nnf-grant-86f16dd91e63956b
OpenAlex ID: G2141568614
